Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Wedbush Raises Price Target on Medtronic (MDT) to $82 Following 4Q Report
June 1, 2016 8:41 AM EDTWedbush reiterated a Neutral rating on Medtronic, Inc. (NYSE: MDT), and raised the price target to $82.00 (from $79.00), following the company's 4Q earnings report. MDT reported revenue of $7,567 million, beating the consensus revenue estimate of $7,479 million and was above the upper end of guidance at... More
Leerink Partners Raises Price Target on Medtronic (MDT) Following 4Q Report
June 1, 2016 7:49 AM EDTLeerink Partners reiterated a Market Perform rating on Medtronic, Inc. (NYSE: MDT), and raised the price target to $85.00 (from $82.00), following the company's 4Q earnings report. MDT delivered its 6th consecutive quarter of mid- to high-single-digit sales growth, building a consistent track record.
Analyst Danielle Antalffy commented, "MDT shares traded lower yesterday driven by what we believe were expectations of more positive operating leverage than the company delivered, potentially as well as a more... More
BTIG Downgrades Medtronic, Inc. (MDT) to Neutral
June 1, 2016 7:18 AM EDTBTIG downgraded Medtronic, Inc. (NYSE: MDT) from Buy to Neutral. Analyst Sean Lavin sees valuation as full and he noted disappointing margins.
"Foremost, at ~$80 we feel valuation is full and no longer see 15% upside over the next 12 months. We also feel... More
Medtronic (MDT): In-Line Quarter, Raising PT - Piper Jaffray
June 1, 2016 6:58 AM EDTPiper Jaffray analyst, Brooks West, raised his PT on Medtronic (NYSE: MDT) to $93 from $85 after the company reported F4Q revenue of $7.57B (+6%cc) vs. consensus of $7.49B. EPS of $1.27, was $0.01 above consensus but the Streets expectation for 300bp of sequential operating leverage... More
Medtronic (MDT) Tops Q4 EPS by 1c
May 31, 2016 6:47 AM EDTMedtronic (NYSE: MDT) reported Q4 EPS of $1.27, $0.01 better than the analyst estimate of $1.26. Revenue for the quarter came in at $7.57 billion versus the consensus estimate of $7.49 billion.
GUIDANCE:
Medtronic sees FY2017 EPS of $4.60-$4.70, versus the consensus of $4.70.
In fiscal... More
